Page last updated: 2024-12-07
penicillin x
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
penicillin X: RN given refers to (2S-(2alpha,5alpha,6beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 120720 |
| CHEBI ID | 81065 |
| SCHEMBL ID | 5930569 |
| MeSH ID | M0114211 |
Synonyms (19)
| Synonym |
|---|
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(2-(p-hydroxyphenyl)acetamido)-7-oxo- |
| p-hydroxybenzylpenicillin |
| penicillin x |
| penicillin iii |
| brn 0049686 |
| C17404 |
| 525-91-7 |
| unii-w097a2s1du |
| w097a2s1du , |
| 4-27-00-05890 (beilstein handbook reference) |
| benzylpenicillin (benzathine) tetrahydrate impurity g [ep impurity] |
| penicillin g sodium impurity c [ep impurity] |
| benzathine benzylpenicillin impurity g [ep impurity] |
| (2s,5r,6r)-6-(2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2-(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)- |
| SCHEMBL5930569 |
| CHEBI:81065 |
| DTXSID20200505 |
| Q27155022 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In both man and rabbit, penicillin X provided higher and more sustained blood levels than did penicillins F or G similarly administered in equal dosage (0." | ( THE VARYING BLOOD LEVELS AFFORDED BY PENICILLINS F, G, K, AND X IN RABBITS AND MAN. Eagle, H, 1947) | 0.53 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| penicillin | Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (25)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 23 (92.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 32.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.01) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||